Kallisio: Advancing Precision Oncology with Patient-Specific Medical Devices

Reducing Friction in Oncology Workflows

Radiation oncology environments often rely on multiple imaging and clinical software systems, making the integration of new technologies challenging. Kallisio addresses this issue through its automated scan-to-print platform, which enables patient-specific device production without requiring additional IT integration. This allows healthcare providers to incorporate personalized treatment solutions into existing workflows with minimal disruption.

Custom 3D-Printed Immobilization Device of the Year 2026

The company's flagship product, Stentra, is an FDA 510(k)-cleared and CE-marked intraoral stent designed for patients undergoing head and neck radiation therapy. The device positions and immobilizes the tongue and jaw while displacing healthy tissue away from the treatment field, helping reduce treatment-related side effects and interruptions. Manufactured through 3D printing from an intraoral scan, each device can be produced in less than 72 hours and is reimbursable in the United States under an established CPT code.

“We see a long-term opportunity in becoming the patient-specific device layer for precision oncology, and Stentra is the first proof point of that platform,” says Rajan Patel, CEO.

Clinics upload patient scans through a HIPAA-compliant cloud portal, enabling efficient manufacturing and delivery. Automated software-generated designs replace traditional dental-lab fabrication processes, reducing turnaround times, minimizing manual adjustments, and improving consistency across devices.

Expanding Beyond a Single Product

Kallisio operates a distributed manufacturing model across the U.S. and Europe, partnering with certified regional 3D-printing facilities to accelerate fulfillment and reduce logistical challenges. Quality assurance is embedded throughout the digital production workflow, ensuring consistent device performance regardless of production location.

The technology behind Stentra originated at The University of Texas MD Anderson Cancer Center and has since been adopted and evaluated by leading institutions, including Stanford Health Care, UPMC Hillman Cancer Center, Penn Medicine, and Fox Chase. Pilot programs have demonstrated improvements in workflow efficiency, treatment continuity, and patient experience while maintaining high levels of operational consistency.

Building on this success, Kallisio is exploring additional patient-specific applications in breast, liver, pancreatic, and prostate cancer treatments. The company is also developing an intraoral cooling device designed to help prevent chemotherapy-induced oral mucositis, with regulatory submission and clinical studies currently in preparation.

By combining automation, distributed manufacturing, and personalized device design, Kallisio is helping healthcare providers make precision oncology more accessible and scalable. Its scan-to-print platform represents a significant step toward individualized cancer treatment, enabling hospitals to adopt patient-specific care solutions more efficiently across a wide range of oncology applications.Read more